Auxilium Pharmaceuticals (AUXL) 19.79 $AUXL
Auxilium Pharmaceuticals Earnings Review: 7 Days after Announcement Shares Down 3.3% (AUXL)
Comtex SmarTrend(R) - Mon May 12, 11:22AM CDT
7 days ago, on May 5th, 2014, Auxilium Pharmaceuticals (NASDAQ:AUXL) reported its earnings. Analysts, on average, expected a loss of $0.22 per share on sales of $86.9 million. The company actually reported a loss of $0.39 per share on sales of $88.5 million, missing EPS estimates by $0.17 and beating revenue estimates by $1.7 million. Shares of Auxilium Pharmaceuticals have slipped from $21.50 to $20.78, representing a loss of 3.3%, since the company reported earnings 7 days ago.
Auxilium Pharmaceuticals, Inc. To Present At The UBS Healthcare Conference
PR Newswire - Mon May 12, 5:00AM CDT
Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL), a fully integrated specialty biopharmaceutical company, today announced that certain members of the executive management team will participate in the UBS Healthcare Conference to be held May 19-21, 2014 at the Sheraton Times Square in New York. Adrian Adams, Chief Executive Officer and President, is scheduled to present an overview of the Company and its product portfolio at 11:00 a.m. ET on Monday, May 19, 2014.
Weakness Seen in Auxiliam Pharmaceutical (AUXL) Estimates: Should You Stay Away? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu May 08, 7:48AM CDT
Auxiliam Pharmaceutical has seen negative earnings estimate revisions for the current quarter along with a significant decline in its share price for the past month
Auxilium Pharmaceuticals, Inc. To Present At The Bank Of America Merrill Lynch Healthcare Conference
PR Newswire - Wed May 07, 5:00AM CDT
Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL), a fully integrated specialty biopharmaceutical company, today announced that certain members of the executive management team will participate in the Bank of America Merrill Lynch Healthcare Conference to be held May 13-15, 2014 at the Wynn Hotel in Las Vegas. Adrian Adams, Chief Executive Officer and President, is scheduled to present an overview of the Company and its product portfolio at 9:20 a.m. ET on Wednesday, May 14, 2014.
Wider-than-Expected Loss at Auxilium - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue May 06, 10:20AM CDT
Auxilium Pharmaceuticals, Inc. (AUXL) reported first quarter 2014 loss (including stock-based compensation expense) of 47 cents per share.
VIVUS Reports Narrower-than-Expected Loss - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue May 06, 10:00AM CDT
VIVUS Inc.'s (VVUS) first quarter 2014 loss (excluding one-time items) of 13 cents per share.
Zacks Rank #5 Additions for Tuesday - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue May 06, 8:30AM CDT
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List for Tuesday
Auxilium Testim sales fall 76%
at Investor's Business Daily - Mon May 05, 5:45PM CDT
The biotech lost 39 cents a share, narrowing from 50 cents a year earlier, but more than double the expected Q1 loss of 17 cents. Sales rose 34% to $88.5 mil vs. views for $89.2 mil. Sales of its testosterone replacement therapy Testim tumbled 76% in...
Target and JPMorgan are big market movers
AP - Mon May 05, 3:35PM CDT
NEW YORK (AP) — Stocks that moved substantially or traded heavily Monday on the New York Stock Exchange and the Nasdaq Stock Market:
Monday’s Top Health Care Stories: Pfizer, Auxilium, and Regeneron
Leo Sun, The Motley Fool - Motley Fool - Mon May 05, 8:20AM CDT
Let's take a look at three stocks -- Pfizer , Auxilium Pharmaceuticals , and Regeneron -- which could make waves across the health care sector this Monday morning. Pfizer misses revenue estimates for the first quarter First up,...
Auxilium Pharmaceuticals incurs higher net loss of USD19.4m for Q1 2014
M2 - Mon May 05, 7:22AM CDT
Biopharmaceutical company Auxilium Pharmaceuticals (NasdaqGS:AUXL) reported on Monday a net loss of USD19.4m (USD0.39 per share, basic and fully diluted) for the first quarter ending 31 March 2014.
Auxilium Pharmaceuticals, Inc. Announces First Quarter 2014 Financial Results
PR Newswire - Mon May 05, 5:00AM CDT
Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL), a fully integrated specialty biopharmaceutical company, today announced financial results for the first quarter ending March 31, 2014. The Company highlighted important commercial, regulatory and clinical development updates from the quarter and, as previously announced, revised its 2014 financial guidance, principally related to lower expectations for Testim® revenues for the year.
Downgrade Alert for Auxilium Pharmaceuticals (AUXL)
Comtex SmarTrend(R) - Thu May 01, 7:07AM CDT
Auxilium Pharmaceuticals (NASDAQ:AUXL) was downgraded from Outperform to Market Perform at Cowen and Company today. The stock closed yesterday at $22.51 on volume of 6.3 million shares, above average daily volume of 1.2 million. There is potential upside of 45.6% for shares of Auxilium Pharmaceuticals based on a current price of $22.51 and an average consensus analyst price target of $32.77. Auxilium Pharmaceuticals shares should encounter resistance at the 50-day moving average (MA) of $28.26 and support at its 200-day MA of $21.84.
Auxilium Pharmaceuticals, Inc. to Present at the Deutsche Bank Healthcare Conference
PR Newswire - Thu May 01, 5:00AM CDT
Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL), a fully integrated specialty biopharmaceutical company, today announced that certain members of the executive management team will participate in the Deutsche Bank Healthcare Conference to be held May 7-8, 2014 at the InterContinental Hotel in Boston. Adrian Adams, Chief Executive Officer and President, is scheduled to present an overview of the Company and its product portfolio at 8:40 a.m. ET on Thursday, May 8, 2014.
After Yesterday's Decline of 17.73%, Auxilium Pharmaceuticals Offers Investors Better Value
Comtex SmarTrend(R) - Wed Apr 30, 5:17PM CDT
Auxilium Pharmaceuticals (NASDAQ:AUXL) traded in a range yesterday that spanned from a low of $21.51 to a high of $24.25. Yesterday, the shares fell 17.7%, which took the trading range below the 3-day low of $25.64 on volume of 6.3 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
Nasdaq stocks posting largest percentage decreases
AP - Wed Apr 30, 5:07PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at the close of trading:
Auxilium Pharma Cuts Guidance - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Apr 30, 4:20PM CDT
Auxilium Pharma lowered its guidance for 2014 and cut its revenue guidance by $70 million to $380 million - $420 million.
Biotech Stock Roundup: Gilead's Sovaldi Shines, Biogen & Alexion Up Outlook - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Apr 30, 9:55AM CDT
Gilead's (GILD) Sovaldi remained in the limelight with sales blowing past expectations.
Wednesday’s Top Health Care Stories: Auxilium, Johnson & Johnson, and Synergy
Leo Sun, The Motley Fool - Motley Fool - Wed Apr 30, 7:58AM CDT
Let's take a look at three stocks -- Auxilium Pharmaceuticals , Johnson & Johnson , and Synergy Pharmaceuticals -- which could all loom large in health care headlines this Wednesday morning. Auxilium lowers its full year guidance...
Auxilium Pharmaceuticals Earnings Review: 7 Days after Announcement Shares Down 3.3% (AUXL)
Comtex SmarTrend(R) - Mon May 12, 11:22AM CDT
7 days ago, on May 5th, 2014, Auxilium Pharmaceuticals (NASDAQ:AUXL) reported its earnings. Analysts, on average, expected a loss of $0.22 per share on sales of $86.9 million. The company actually reported a loss of $0.39 per share on sales of $88.5 million, missing EPS estimates by $0.17 and beating revenue estimates by $1.7 million. Shares of Auxilium Pharmaceuticals have slipped from $21.50 to $20.78, representing a loss of 3.3%, since the company reported earnings 7 days ago.
Auxilium Pharmaceuticals, Inc. To Present At The UBS Healthcare Conference
PR Newswire - Mon May 12, 5:00AM CDT
Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL), a fully integrated specialty biopharmaceutical company, today announced that certain members of the executive management team will participate in the UBS Healthcare Conference to be held May 19-21, 2014 at the Sheraton Times Square in New York. Adrian Adams, Chief Executive Officer and President, is scheduled to present an overview of the Company and its product portfolio at 11:00 a.m. ET on Monday, May 19, 2014.
Weakness Seen in Auxiliam Pharmaceutical (AUXL) Estimates: Should You Stay Away? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu May 08, 7:48AM CDT
Auxiliam Pharmaceutical has seen negative earnings estimate revisions for the current quarter along with a significant decline in its share price for the past month
Auxilium Pharmaceuticals, Inc. To Present At The Bank Of America Merrill Lynch Healthcare Conference
PR Newswire - Wed May 07, 5:00AM CDT
Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL), a fully integrated specialty biopharmaceutical company, today announced that certain members of the executive management team will participate in the Bank of America Merrill Lynch Healthcare Conference to be held May 13-15, 2014 at the Wynn Hotel in Las Vegas. Adrian Adams, Chief Executive Officer and President, is scheduled to present an overview of the Company and its product portfolio at 9:20 a.m. ET on Wednesday, May 14, 2014.
Wider-than-Expected Loss at Auxilium - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue May 06, 10:20AM CDT
Auxilium Pharmaceuticals, Inc. (AUXL) reported first quarter 2014 loss (including stock-based compensation expense) of 47 cents per share.
VIVUS Reports Narrower-than-Expected Loss - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue May 06, 10:00AM CDT
VIVUS Inc.'s (VVUS) first quarter 2014 loss (excluding one-time items) of 13 cents per share.
Zacks Rank #5 Additions for Tuesday - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue May 06, 8:30AM CDT
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List for Tuesday
Auxilium Testim sales fall 76%
at Investor's Business Daily - Mon May 05, 5:45PM CDT
The biotech lost 39 cents a share, narrowing from 50 cents a year earlier, but more than double the expected Q1 loss of 17 cents. Sales rose 34% to $88.5 mil vs. views for $89.2 mil. Sales of its testosterone replacement therapy Testim tumbled 76% in...
Target and JPMorgan are big market movers
AP - Mon May 05, 3:35PM CDT
NEW YORK (AP) — Stocks that moved substantially or traded heavily Monday on the New York Stock Exchange and the Nasdaq Stock Market:
Monday’s Top Health Care Stories: Pfizer, Auxilium, and Regeneron
Leo Sun, The Motley Fool - Motley Fool - Mon May 05, 8:20AM CDT
Let's take a look at three stocks -- Pfizer , Auxilium Pharmaceuticals , and Regeneron -- which could make waves across the health care sector this Monday morning. Pfizer misses revenue estimates for the first quarter First up,...
Auxilium Pharmaceuticals incurs higher net loss of USD19.4m for Q1 2014
M2 - Mon May 05, 7:22AM CDT
Biopharmaceutical company Auxilium Pharmaceuticals (NasdaqGS:AUXL) reported on Monday a net loss of USD19.4m (USD0.39 per share, basic and fully diluted) for the first quarter ending 31 March 2014.
Auxilium Pharmaceuticals, Inc. Announces First Quarter 2014 Financial Results
PR Newswire - Mon May 05, 5:00AM CDT
Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL), a fully integrated specialty biopharmaceutical company, today announced financial results for the first quarter ending March 31, 2014. The Company highlighted important commercial, regulatory and clinical development updates from the quarter and, as previously announced, revised its 2014 financial guidance, principally related to lower expectations for Testim® revenues for the year.
Downgrade Alert for Auxilium Pharmaceuticals (AUXL)
Comtex SmarTrend(R) - Thu May 01, 7:07AM CDT
Auxilium Pharmaceuticals (NASDAQ:AUXL) was downgraded from Outperform to Market Perform at Cowen and Company today. The stock closed yesterday at $22.51 on volume of 6.3 million shares, above average daily volume of 1.2 million. There is potential upside of 45.6% for shares of Auxilium Pharmaceuticals based on a current price of $22.51 and an average consensus analyst price target of $32.77. Auxilium Pharmaceuticals shares should encounter resistance at the 50-day moving average (MA) of $28.26 and support at its 200-day MA of $21.84.
Auxilium Pharmaceuticals, Inc. to Present at the Deutsche Bank Healthcare Conference
PR Newswire - Thu May 01, 5:00AM CDT
Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL), a fully integrated specialty biopharmaceutical company, today announced that certain members of the executive management team will participate in the Deutsche Bank Healthcare Conference to be held May 7-8, 2014 at the InterContinental Hotel in Boston. Adrian Adams, Chief Executive Officer and President, is scheduled to present an overview of the Company and its product portfolio at 8:40 a.m. ET on Thursday, May 8, 2014.
After Yesterday's Decline of 17.73%, Auxilium Pharmaceuticals Offers Investors Better Value
Comtex SmarTrend(R) - Wed Apr 30, 5:17PM CDT
Auxilium Pharmaceuticals (NASDAQ:AUXL) traded in a range yesterday that spanned from a low of $21.51 to a high of $24.25. Yesterday, the shares fell 17.7%, which took the trading range below the 3-day low of $25.64 on volume of 6.3 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
Nasdaq stocks posting largest percentage decreases
AP - Wed Apr 30, 5:07PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at the close of trading:
Auxilium Pharma Cuts Guidance - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Apr 30, 4:20PM CDT
Auxilium Pharma lowered its guidance for 2014 and cut its revenue guidance by $70 million to $380 million - $420 million.
Biotech Stock Roundup: Gilead's Sovaldi Shines, Biogen & Alexion Up Outlook - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Apr 30, 9:55AM CDT
Gilead's (GILD) Sovaldi remained in the limelight with sales blowing past expectations.
Wednesday’s Top Health Care Stories: Auxilium, Johnson & Johnson, and Synergy
Leo Sun, The Motley Fool - Motley Fool - Wed Apr 30, 7:58AM CDT
Let's take a look at three stocks -- Auxilium Pharmaceuticals , Johnson & Johnson , and Synergy Pharmaceuticals -- which could all loom large in health care headlines this Wednesday morning. Auxilium lowers its full year guidance...
